Methods of treating cancer with human monoclonal antibodies to CTLA-4
US8491895B2 · kind B2 · utility
18Cited by
67References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 17, 2012 |
| Grant date | Jul 23, 2013 |
| Priority date | — |
| Expiry date | Feb 17, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.